This research develops multimodal contrast-enhanced learning to improve molecular property predictions, indicating enhanced drug discovery potential.
Molecular representation learning (MRL) has garnered significant attention due to its pivotal role in downstream applications such as molecular property prediction and drug discovery. In most MRL approaches, molecules are encoded into 2D topological graphs via graph neural network (GNN), which suffers from over-smoothing issues and limited receptive fields. Furthermore, most GNN models fail to utilize the 3D spatial structural information that determines molecular physicochemical properties and biological activity. To this end, here we propose multimodal contrast-enhanced molecular representation learning (MCMRL). This approach utilizes both the 2D topological information and 3D structural information of molecules for contrastive learning to enhance molecular graph representations. Further, it integrates additional molecular fingerprint information and feature fusion techniques to incorporate multimodal knowledge, yielding more reliable and generalizable molecular representations. MCMRL is pre-trained on ~10 million unlabeled molecules from PubChem, followed by various downstream benchmark tasks. Experimental results demonstrate that MCMRL achieves superior performance in 9 out of 13 benchmark tests for molecular property prediction, validating its effectiveness in molecular representation learning. Furthermore, potential molecular drugs binding to biological target protein DRD2 screened by MCMRL representation show promising affinity score, which also demonstrates the efficacy of the proposed method.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: